Trial · NCT01900665
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 14 Item Subscore (ADAS-Cog14) | Baseline, Week 80 | All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Alzheimer's Disease Cooperative Study- Instrumental Activities of Daily Living (ADCS-iADL) | Baseline, Week 80 | All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 11 Item Subscore (ADAS-Cog11) | Baseline, Week 80 | All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Mini-Mental State Examination (MMSE) | Baseline, Week 80 | All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) | Baseline, Week 80 | All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Functional Activities Questionnaire (FAQ) | Baseline, Week 80 | All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) | Baseline, Week 80 | All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data. | Units on a scale | MEAN |
| SECONDARY | Change From Baseline in Neuropsychiatric Inventory (NPI) | Baseline, Week 80 | All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) | Baseline, Week 80 | All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data. | Number of hospitalizations | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) | Baseline, Week 80 | All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in 5-Dimensional EuroQol Quality of Life Scale Proxy Version (EQ-5D Proxy) | Baseline, Week 80 | All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data. | mm | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) | Baseline, Week 80 | All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data. | units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants of Cognitive and Functional Responders | Baseline through Week 80 | All randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in Plasma Amyloid-Beta (Aβ) Species | Baseline, Week 80 | All randomized participants. | Picogram/milliliter | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) | Baseline, Week 80 | All randomized participants. | Cubic millimeter (mm^3) | MEAN |
| SECONDARY | Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Solanezumab (LY2062430) | Visit 2 (Post-dose), Visit 5, 9, 15 (Pre-dose, Post-dose) and Visit 22 (Pre-dose): Pre-dose before the infusion, Post-dose 30 minutes End of Infusion | All randomized participants who received at least 1 dose of study medication (Solanezumab) with evaluable Solanezumab PK data. | milligram*hour per milliliter (mg*h/mL) | GEOMETRIC_MEAN |
| SECONDARY | Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan | Baseline, Week 80 | All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data. | standard uptake value ratio | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Cerebrospinal Fluid (CSF) Aβ Levels | Baseline, Week 80 | All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data. | picogram/milliliter | LEAST_SQUARES_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01900665/outcomes